| Nuvalent, Inc. |
Director, Director by Deputization, 10%+ Owner |
Class A Common Stock |
8,299,225 |
$792,119,530 |
$95.44 |
24 Nov 2025 |
Through Deerfield Healthcare Innovations Fund, L.P. |
| Nuvalent, Inc. |
Director, Director by Deputization, 10%+ Owner |
Class A Common Stock |
8,299,225 |
$792,119,530 |
$95.44 |
24 Nov 2025 |
Through Deerfield Private Design Fund IV, L.P. |
| AdaptHealth Corp. |
*Possible Member of 10% Group, 10%+ Owner |
Class A Common Stock |
11,528,863 |
$123,358,834 |
$10.7 |
12 Mar 2024 |
Through Deerfield Partners, L.P. |
| ARS Pharmaceuticals, Inc. |
10%+ Owner |
Class A Common Stock |
4,887,254 |
$90,218,708 |
$18.46 |
27 Jun 2025 |
Through Deerfield Private Design Fund III, L.P. |
| ARS Pharmaceuticals, Inc. |
10%+ Owner |
Class A Common Stock |
4,887,254 |
$90,218,708 |
$18.46 |
27 Jun 2025 |
Through Deerfield Private Design Fund IV, L.P. |
| Nuvalent, Inc. |
Director, Director by Deputization, 10%+ Owner |
Class A Common Stock |
650,000 |
$55,029,000 |
$84.66 |
24 Nov 2025 |
Through Deerfield Partners, L.P. |
| CareMax, Inc. |
Director, Director by Deputization, 10%+ Owner |
Class A Common Stock |
15,811,090 |
$54,706,371 |
$3.46 |
17 Nov 2023 |
Through Deerfield Partners, L.P. |
| Mirum Pharmaceuticals, Inc. |
* Possible Member of 10% Group, 10%+ Owner |
Common Stock |
1,704,244 |
$47,778,651 |
$28.04 |
06 Jun 2022 |
Through Deerfield Private Design Fund IV, L.P. |
| Mirum Pharmaceuticals, Inc. |
* Possible Member of 10% Group, 10%+ Owner |
Common Stock |
1,540,190 |
$43,179,381 |
$28.04 |
06 Jun 2022 |
Through Deerfield Healthcare Innovations Fund, L.P. |
| Larimar Therapeutics, Inc. |
Director, * Director by Deputization, 10%+ Owner |
Common Stock |
9,538,945 |
$30,524,624 |
$3.2 |
31 Jul 2025 |
Through Deerfield Private Design Fund IV, L.P. |
| Larimar Therapeutics, Inc. |
Director, * Director by Deputization, 10%+ Owner |
Common Stock |
9,538,918 |
$30,524,537 |
$3.2 |
31 Jul 2025 |
Through Deerfield Private Design Fund III, L.P. |
| Larimar Therapeutics, Inc. |
Director, * Director by Deputization, 10%+ Owner |
Common Stock |
7,321,129 |
$23,427,612 |
$3.2 |
31 Jul 2025 |
Through Deerfield Healthcare Innovations Fund, L.P. |
| AdaptHealth Corp. |
*Possible Member of 10% Group, 10%+ Owner |
Class A Common Stock |
1,709,077 |
$18,287,124 |
$10.7 |
08 Mar 2024 |
Through Deerfield Private Design Fund IV, L.P. |
| Larimar Therapeutics, Inc. |
Director, * Director by Deputization, 10%+ Owner |
Common Stock |
4,207,982 |
$14,643,777 |
$3.48 |
31 Jul 2025 |
Through Deerfield Partners, L.P. |
| Bicara Therapeutics Inc. |
Possible Members of 10% Group, 10%+ Owner |
Common Stock |
897,587 |
$11,887,104 |
$13.24 |
17 Sep 2024 |
Through Deerfield Partners, L.P. |
| Bicara Therapeutics Inc. |
Possible Members of 10% Group, 10%+ Owner |
Common Stock |
897,587 |
$11,887,104 |
$13.24 |
17 Sep 2024 |
Through Deerfield Private Design Fund V, L.P. |
| Singular Genomics Systems, Inc. |
*Possible Member of 10% Group, 10%+ Owner |
Common Stock |
7,484,871 |
$3,169,094 |
$0.4234 |
01 Jun 2021 |
Through Deerfield Private Design Fund IV, L.P. |
| Acutus Medical, Inc. |
Director, Director by deputization |
Common Stock |
1,622,143 |
$2,530,543 |
$1.56 |
27 Jan 2025 |
Through Deerfield Private Design Fund III, L.P. |
| Fractyl Health, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Common Stock |
834,254 |
$2,419,003 |
$2.9 |
06 Feb 2024 |
Through Deerfield Private Design Fund III, L.P. |
| PepGen Inc. |
Possible Member of 10% Group, 10%+ Owner |
Common Stock |
476,813 |
$1,985,926 |
$4.16 |
10 May 2022 |
Through Deerfield Partners, L.P. |
| PepGen Inc. |
Possible Member of 10% Group, 10%+ Owner |
Common Stock |
476,813 |
$1,985,926 |
$4.16 |
10 May 2022 |
Through Deerfield Private Design Fund V, L.P. |
| Acutus Medical, Inc. |
Director, Director by deputization |
Common Stock |
1,026,243 |
$1,600,939 |
$1.56 |
27 Jan 2025 |
Through Deerfield Partners, L.P. |
| BiomX Inc. |
Director, *Director by Deputization |
Common Stock |
1,247,054 |
$1,160,508 |
$0.9306 |
27 Feb 2025 |
Through Deerfield Healthcare Innovations Fund II, L.P. |
| BiomX Inc. |
Director, *Director by Deputization |
Common Stock |
1,247,054 |
$1,160,508 |
$0.9306 |
27 Feb 2025 |
Through Deerfield Private Design Fund V, L.P. |
| Xilio Therapeutics, Inc. |
Possible Member of 10% Group, 10%+ Owner |
Common Stock |
1,143,972 |
$949,497 |
$0.83 |
26 Oct 2021 |
Through Deerfield Partners, L.P. |
| Xilio Therapeutics, Inc. |
Possible Member of 10% Group, 10%+ Owner |
Common Stock |
1,143,972 |
$949,497 |
$0.83 |
26 Oct 2021 |
Through Deerfield Private Design Fund V, L.P. |
| Singular Genomics Systems, Inc. |
*Possible Member of 10% Group, 10%+ Owner |
Common Stock |
1,627,148 |
$688,934 |
$0.4234 |
01 Jun 2021 |
Through Deerfield Partners, L.P. |
| Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Class A Common Stock |
1,605,477 |
$218,345 |
$0.136 |
12 Nov 2021 |
Through Deerfield Partners, L.P. |
| Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Class A Common Stock |
1,605,477 |
$218,345 |
$0.136 |
12 Nov 2021 |
Through Deerfield Private Design Fund IV, L.P. |
| AdaptHealth Corp. |
*Possible Member of 10% Group, 10%+ Owner |
Class A Common Stock |
20,000 |
$214,000 |
$10.7 |
08 Mar 2024 |
Through Deerfield Management Company, L.P. |
| CareMax, Inc. |
Director, Director by Deputization, 10%+ Owner |
Class A Common Stock |
12,123 |
$41,946 |
$3.46 |
17 Nov 2023 |
Through Deerfield Management Company, L.P. |
| Singular Genomics Systems, Inc. |
*Possible Member of 10% Group, 10%+ Owner |
Stock Option (Right to Buy) |
30,000 |
$33,000 |
$1.1 |
01 Jun 2021 |
Through Deerfield Management Company, L.P. |
| Acutus Medical, Inc. |
Director, Director by deputization |
Common Stock |
20,822 |
$32,482 |
$1.56 |
27 Jan 2025 |
Through Deerfield Management Company, L.P. |
| Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Class A Common Stock |
85,113 |
$11,575 |
$0.136 |
12 Nov 2021 |
Through Deerfield Management Company, L.P. |
| Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Class A Common Stock |
40 |
$5 |
$0.136 |
12 Nov 2021 |
Through DFP Sponsor, LLC |
| Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Private Placement Warrants |
3,177,543 |
|
|
12 Nov 2021 |
Through DFP Sponsor, LLC |
| Frazier Lifesciences Acquisition Corp |
Possible Member of 10% Group, 10%+ Owner |
Class A Ordinary Shares |
2,480,199 |
|
|
08 Nov 2022 |
Through Deerfield Partners, L.P. |
| Acutus Medical, Inc. |
Director, Director by deputization |
Series A Common Stock Equivalent Convertible Preferred Stock |
1,816,446 |
|
|
27 Jan 2025 |
Through Deerfield Private Design Fund III, L.P. |
| BiomX Inc. |
Director, *Director by Deputization |
Warrants |
1,611,864 |
|
|
21 Apr 2025 |
Through Deerfield Healthcare Innovations Fund II, L.P. |
| BiomX Inc. |
Director, *Director by Deputization |
Warrants |
1,611,864 |
|
|
21 Apr 2025 |
Through Deerfield Private Design Fund V, L.P. |
| Oncorus, Inc. |
Possible Member of 10% Group, 10%+ Owner |
Common Stock |
1,156,309 |
|
|
30 Dec 2022 |
Through Deerfield Healthcare Innovations Fund, L.P. |
| Oncorus, Inc. |
Possible Member of 10% Group, 10%+ Owner |
Common Stock |
1,156,308 |
|
|
30 Dec 2022 |
Through Deerfield Private Design Fund III, L.P. |
| Acutus Medical, Inc. |
Director, Director by deputization |
Series A Common Stock Equivalent Convertible Preferred Stock |
948,395 |
|
|
27 Jan 2025 |
Through Deerfield Partners, L.P. |
| Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Public Warrants |
625,000 |
|
|
12 Nov 2021 |
Through Deerfield Partners, L.P. |
| Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Public Warrants |
625,000 |
|
|
12 Nov 2021 |
Through Deerfield Private Design Fund IV, L.P. |
| Oncorus, Inc. |
Possible Member of 10% Group, 10%+ Owner |
Common Stock |
284,697 |
|
|
30 Dec 2022 |
Through Deerfield Partners, L.P. |
| Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Series A Common Stock Equivalent Convertible Preferred Stock |
58,945 |
|
|
12 Nov 2021 |
Through Deerfield Partners, L.P. |
| Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Series A Common Stock Equivalent Convertible Preferred Stock |
58,945 |
|
|
12 Nov 2021 |
Through Deerfield Private Design Fund IV, L.P. |
| BiomX Inc. |
Director, *Director by Deputization |
Series X Non-Voting Convertible Preferred Stock |
47,957 |
|
|
15 Jul 2024 |
Through Deerfield Healthcare Innovations Fund II, L.P. |
| BiomX Inc. |
Director, *Director by Deputization |
Series X Non-Voting Convertible Preferred Stock |
47,957 |
|
|
15 Jul 2024 |
Through Deerfield Private Design Fund V, L.P. |
| Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Series A Common Stock Equivalent Convertible Preferred Stock |
45,620 |
|
|
12 Nov 2021 |
Through DFP Sponsor, LLC |
| Larimar Therapeutics, Inc. |
Director, * Director by Deputization, 10%+ Owner |
Stock Option (Right to Buy) |
19,000 |
|
|
13 May 2025 |
Through Deerfield Management Company, L.P. |
| BiomX Inc. |
Director, *Director by Deputization |
Stock Option (Right to Buy) |
17,600 |
|
|
14 Apr 2025 |
Through Deerfield Management Company, L.P. |
| Nuvalent, Inc. |
Director, Director by Deputization, 10%+ Owner |
Stock Option (Right to Buy) |
4,147 |
|
|
18 Jun 2025 |
Through Deerfield Management Company, L.P. |
| Acutus Medical, Inc. |
Director, Director by deputization |
Warrant to Purchase Common Stock |
0 |
|
|
27 Jan 2025 |
Through Deerfield Partners, L.P. |
| Acutus Medical, Inc. |
Director, Director by deputization |
Warrant to Purchase Common Stock |
0 |
|
|
27 Jan 2025 |
Through Deerfield Private Design Fund III, L.P. |
| Bicara Therapeutics Inc. |
Possible Members of 10% Group, 10%+ Owner |
Series C Preferred Stock |
0 |
|
|
17 Sep 2024 |
Through Deerfield Partners, L.P. |
| Bicara Therapeutics Inc. |
Possible Members of 10% Group, 10%+ Owner |
Series C Preferred Stock |
0 |
|
|
17 Sep 2024 |
Through Deerfield Private Design Fund V, L.P. |
| CareMax, Inc. |
Director, Director by Deputization, 10%+ Owner |
Restricted Stock Units |
0 |
|
$3.46 |
17 Nov 2023 |
Through Deerfield Management Company, L.P. |
| Fractyl Health, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Series C-2 Preferred Stock |
0 |
|
|
06 Feb 2024 |
Through Deerfield Private Design Fund III, L.P. |
| Fractyl Health, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Series D Preferred Stock |
0 |
|
|
06 Feb 2024 |
Through Deerfield Private Design Fund III, L.P. |
| Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Class B Common Stock |
0 |
|
|
12 Nov 2021 |
Through Deerfield Management Company, L.P. |
| Oncology Institute, Inc. |
Possible Members of 10% Group, 10%+ Owner |
Class B Common Stock |
0 |
|
|
12 Nov 2021 |
Through DFP Sponsor, LLC |
| PepGen Inc. |
Possible Member of 10% Group, 10%+ Owner |
Series B Preferred Stock |
0 |
|
|
10 May 2022 |
Through Deerfield Partners, L.P. |
| PepGen Inc. |
Possible Member of 10% Group, 10%+ Owner |
Series B Preferred Stock |
0 |
|
|
10 May 2022 |
Through Deerfield Private Design Fund V, L.P. |
| Singular Genomics Systems, Inc. |
*Possible Member of 10% Group, 10%+ Owner |
6% Convertible Note due 2023 |
0 |
|
|
01 Jun 2021 |
Through Deerfield Partners, L.P. |
| Singular Genomics Systems, Inc. |
*Possible Member of 10% Group, 10%+ Owner |
6% Convertible Note due 2023 |
0 |
|
|
01 Jun 2021 |
Through Deerfield Private Design Fund IV, L.P. |
| Singular Genomics Systems, Inc. |
*Possible Member of 10% Group, 10%+ Owner |
Series B Preferred Stock |
0 |
|
|
01 Jun 2021 |
Through Deerfield Private Design Fund IV, L.P. |
| Xilio Therapeutics, Inc. |
Possible Member of 10% Group, 10%+ Owner |
Series C Preferred Stock |
0 |
|
|
26 Oct 2021 |
Through Deerfield Partners, L.P. |
| Xilio Therapeutics, Inc. |
Possible Member of 10% Group, 10%+ Owner |
Series C Preferred Stock |
0 |
|
|
26 Oct 2021 |
Through Deerfield Private Design Fund V, L.P. |